Hypha Labs (FUNI) 10-Q 14 Feb 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Dec. 31, 2022	Feb. 14, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--09-30
Entity File Number	000-54239
Entity Registrant Name	Digipath, Inc.
Entity Central Index Key	0001502966
Entity Tax Identification Number	27-3601979
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	6450 Cameron St
Entity Address, Address Line Two	Suite 113
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	(702)
Local Phone Number	527-2060
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		86,696,820

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Current assets:
Cash	$ 155,832	$ 56,168
Accounts receivable, net	301,870	335,085
Deposits	20,700	25,141
Note receivable		100,000
Other current assets	29,852	45,710
Total current assets	508,254	562,104
Right-of-use asset	291,869	316,961
Fixed assets, net	378,806	460,823
Total non-current assets	670,675	777,784
Total Assets	1,178,929	1,339,888
Current liabilities:
Accounts payable	571,121	550,467
Accrued expenses	420,030	378,368
Current portion of operating lease liabilities	105,649	100,685
Current maturities of notes payable	726,800	725,920
Current maturities of convertible notes payable, net of discounts	150,000	1,198,469
Total current liabilities	1,973,600	2,953,909
Non-current liabilities:
Operating lease liabilities	199,597	229,825
Notes payable	64,644	80,428
Convertible notes payable related parties, net of discounts	317,597	310,272
Convertible notes payable, net of discounts and current maturities	1,170,849	174,726
Total non-current liabilities	1,752,687	795,251
Total Liabilities	3,726,287	3,749,160
Series B convertible preferred stock, $0.001 par value, 1,500,000 shares authorized; 333,600 shares issued and outstanding as of December 31, 2022 and September 30, 2022	333,600	333,600
Stockholders’ Deficit:
Common stock, $0.001 par value, 250,000,000 shares authorized; 82,296,820 and 75,146,820 shares issued and outstanding at December 31, 2022 and September 30, 2022, respectively	82,297	75,147
Common stock payable		71,745
Additional paid-in capital	17,284,797	17,117,958
Accumulated deficit	(20,249,101)	(20,008,771)
Total Stockholders’ Deficit	(2,880,958)	(2,742,872)
Total Liabilities and Stockholders’ Deficit	1,178,929	1,339,888
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock	1,048	1,048
Series C Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock	$ 1	$ 1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Sep. 30, 2022
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	82,296,820	75,146,820
Common stock, shares outstanding	82,296,820	75,146,820
Series B Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	333,600
Temporary equity, shares outstanding	333,600	333,600
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	1,047,942	1,047,942
Preferred stock, shares outstanding	1,047,942	1,047,942
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	1,000	1,000
Preferred stock, shares outstanding	1,000	1,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues	$ 726,755	$ 699,585
Cost of sales	422,835	422,601
Gross profit	303,920	276,984
Operating expenses:
General and administrative	306,483	240,964
Professional fees	69,969	255,749
Change in allowance for doubtful accounts	13,685	(2,139)
Total operating expenses	390,137	494,574
Operating loss	(86,217)	(217,590)
Other income (expense):
Other Expense	(55,000)
Interest income		9,380
Interest expense	(99,113)	(69,393)
Total other income (expense)	(154,113)	(60,013)
Net loss	(240,330)	(277,603)
Preferred deemed dividend		(192,154)
Net loss to common shareholders	$ (240,330)	$ (469,757)
Weighted average number of common shares outstanding - basic and fully diluted	82,219,103	72,387,762
Net loss per share - basic and fully diluted	$ 0	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Stock Payable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Sep. 30, 2021		$ 1,326		$ 71,230		$ 16,825,765	$ (17,951,653)	$ (1,053,332)
Beginning balance, shares at Sep. 30, 2021		1,325,942		71,230,153
Stock-based compensation						33,457		33,457
Net loss							(277,603)	(277,603)
Series B Preferred shares sold for cash	$ 55,600
Series B Preferred shares sold for cash, shares	55,600
Conversion of Series A Preferred Shares into Series B Preferred	$ 278,000	$ (278)				(85,568)		(85,846)
Conversion of Series A Preferred Shares into Series B Preferred, shares	278,000	(278,000)
Common stock issued for services				$ 1,500		51,000		52,500
Common stock issued for services, shares				1,500,000
Deemed dividend on preferred exchange						(192,154)		(192,154)
Ending balance, value at Dec. 31, 2021	$ 333,600	$ 1,048		$ 72,730		16,632,500	(18,229,256)	(1,522,978)
Ending balance, shares at Dec. 31, 2021	333,600	1,047,942		72,730,153
Beginning balance, value at Sep. 30, 2022	$ 333,600	$ 1,048	$ 1	$ 75,147	71,745	17,117,958	(20,008,771)	(2,742,872)
Beginning balance, shares at Sep. 30, 2022	333,600	1,047,942	1,000	75,146,820
Issuance of common shares to settle stock payable				$ 7,150	(71,745)	64,595
Issuance of common shares to settle stock payable, shares				7,150,000
Warrants issued as debt financing costs						93,938		93,938
Stock-based compensation						8,306		8,306
Net loss							(240,330)	(240,330)
Ending balance, value at Dec. 31, 2022	$ 333,600	$ 1,048	$ 1	$ 82,297		$ 17,284,797	$ (20,249,101)	$ (2,880,958)
Ending balance, shares at Dec. 31, 2022	333,600	1,047,942	1,000	82,296,820

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (240,330)	$ (277,603)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in allowance for doubtful accounts	13,685	(2,139)
Depreciation and amortization expense	35,759	58,469
Stock-based compensation	8,306	85,957
Amortization of debt discounts	48,916	19,766
Impairment of fixed assets	55,000
Decrease (increase) in assets:
Accounts receivable	19,530	(113,359)
Other current assets	15,858	6,984
Deposits	(1,635)	(390)
Right-of-use assets	25,092	23,734
Increase (decrease) in liabilities:
Accounts payable	20,655	(2,951)
Accrued expenses	41,662	46,956
Lease liabilities	(25,264)	(22,582)
Net cash provided by (used in) operating activities	17,234	(177,158)
Cash flows from investing activities
Purchase of fixed assets	(2,666)	(2,482)
Advance of note receivable		(406,000)
Proceeds from sale of collateralized assets	100,000
Net cash provided by (used in) investing activities	97,334	(408,482)
Cash flows from financing activities
Principal payments on finance lease		(8,467)
Principal payments on note payable, equipment financing	(14,904)	(14,142)
Proceeds from notes payable		400,000
Proceeds from convertible notes
Payments on convertible notes		(52,978)
Proceeds from sale of common stock
Proceeds from sale of preferred stock		55,600
Net cash provided by (used in) financing activities	(14,904)	380,013
Net increase (decrease) in cash	99,664	(205,627)
Cash - beginning	56,168	295,932	$ 295,932
Cash - ending	155,832	90,305	$ 56,168
Supplemental disclosures:
Interest paid	26,166	27,601
Income taxes paid
Non-cash investing and financing activities:
Common stock issued for settlement of stock payable	71,745
Warrants issued for debt financing	93,938
Transfer of completed assets	6,076
Conversion of Series A preferred into Series B preferred		85,846
Deemed dividend on preferred exchange		$ 192,154

Organization, Basis of Presenta

Organization, Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Organization, Basis of Presentation and Significant Accounting Policies	Note 1 – Organization, Basis of Presentation and Significant Accounting Policies Organization Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and hopes to open labs in other states that have legalized the sale of cannabis, beginning with California or Arizona. Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2022: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc. (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the three months ended December 31, 2022 and 2021, potential dilutive securities of 91,161,317 50,368,696 6,020,000 6,020,000 15,387,050 2,535,001 13,579,710 13,579,710 Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity).

Going Concern

Going Concern	3 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying condensed consolidated financial statements, as of December 31, 2022, the Company had negative working capital of $ 1,465,347 20,249,101 155,832 The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments The Company discloses the fair value of certain assets and liabilities in accordance with ASC 820 – Fair Value Measurement The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of December 31, 2022 and September 30, 2022, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 155,832 $ - $ - Liabilities Lease liabilities - - 305,246 Notes payable - 791,444 - Convertible notes payable, net of discounts of $ 97,387 - - 1,320,849 Convertible notes payable – related parties, net of discounts of $ 32,403 - - 317,597 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 56,168 $ - $ - Liabilities Lease liabilities - - 330,510 Notes payable - 806,348 - Convertible notes payable, net of discounts of $ 45,039 - - 1,373,195 Convertible notes payable – related parties, net of discounts of $ 39,728 - - 310,272 Convertible notes payable, net - - 1,373,195 Convertible notes payable – related parties, net - - 310,272 The fair value of our intellectual properties are deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the three months ended December 31, 2022.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 – Related Party Transactions During the three months ended December 31, 2022 the Company incurred fees of $ 15,000 30,000 During the three months ended December 31, 2022 the Company incurred fees of $ 21,000 147,000

Note Receivable

Note Receivable	3 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Note Receivable	Note 5 – Note Receivable On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $ 95,000 10 On various dates between August 23, 2021 and September 30, 2022, we loaned C3 Labs, Inc. (“C3 Labs”) a total of $ 1,047,649 8 August 23, 2022 64,017 The loans were made in connection with a potential acquisition of a controlling interest in C3 Labs pursuant to a letter of intent. On March 11, 2022, the Company notified the current owners of C3 Labs of its termination of the letter of intent and took possession of the equipment of C3 Labs (“C3 Equipment”), which it is in the process of being liquidated. On December 8, 2022, the Company entered into an Asset Purchase Agreement with Invictus Wealth Group (“Invictus”), whereby the Company agreed to sell the C3 Equipment to Invictus for a total purchase price of $ 900,000 275,000 625,000 December 31, 2023 10 100,000 425,000 100,000 275,000

Fixed Assets

Fixed Assets	3 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 6 – Fixed Assets Fixed assets consist of the following at December 31, 2022 and September 30, 2022: Schedule of Fixed Assets December, September 30, 2022 2022 Software $ 125,903 $ 125,903 Office equipment 80,343 71,601 Furniture and fixtures 29,879 29,879 Lab equipment 1,400,479 1,455,479 Leasehold improvements 510,076 510,076 Lab equipment held under capital leases 99,193 99,193 Fixed assets, gross 2,245,873 2,292,131 Less: accumulated depreciation (1,867,067 ) (1,831,308 ) Total $ 378,806 $ 460,823 Depreciation and amortization expense totaled $ 35,759 58,469 During the three months ended December 31, 2022, the Company recorded impairment expense in the amount of $ 55,000

Leases

Leases	3 Months Ended
	Dec. 31, 2022
Leases
Leases	Note 7 – Leases The Company leases its operating and office facility under a non-cancelable real property lease agreement that expires on August 31, 2025 The components of lease expense were as follows: Schedule of Components of Lease Expense For the For the Three Months Ended Three Months Ended December 31, December 31, 2022 2021 Operating lease cost $ 29,718 $ 29,718 Finance lease cost: Amortization of assets - 8,467 Interest on lease liabilities - 809 Total net lease cost $ 29,718 $ 38,994 Supplemental balance sheet information related to leases was as follows: Schedule of Supplemental Balance Sheet Information December 31, September 30, 2022 2022 Operating leases: Operating lease assets $ 291,869 $ 316,961 Current portion of operating lease liabilities 105,649 $ 100,685 Noncurrent operating lease liabilities 199,597 229,825 Total operating lease liabilities $ 305,246 $ 330,510 Finance lease: Equipment, at cost $ 99,193 $ 99,193 Accumulated amortization (64,475 ) (59,516 ) Equipment, net $ 34,718 $ 39,677 Weighted average remaining lease term: Operating leases 2.67 2.92 Weighted average discount rate: Operating leases 5.75 % 5.75 % Supplemental cash flow and other information related to leases was as follows: Schedule of Supplemental Cash Flow and Other Information For the Three For the Three Months Ended Months Ended December 31, December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used for operating leases $ 29,532 $ 22,582 Financing cash flows used for finance leases $ - $ 8,467 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ - $ - Total finance lease liabilities $ - $ - The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of December 31, 2022: Schedule of Future Minimum Annual Lease Commitments Under Operating Leases Fiscal Year Ending Minimum Lease September 30, Commitments 2023 $ 89,936 2024 123,543 2025 116,891 2026 - 2027 - Total future undiscounted lease payments 330,370 Less interest 25,124 Present value of lease payments 305,246 Less current portion 105,649 Long-term operating lease liabilities $ 199,597

Notes Payable

Notes Payable	3 Months Ended
	Dec. 31, 2022
Long-Term Debt, Unclassified [Abstract]
Notes Payable	Note 8 – Notes Payable Notes payable consists of the following at December 31, 2022 and September 30, 2022, respectively: Schedule of Notes Payable December 31, 2022 September 30, 2022 On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ 665,000 $ 665,000 On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 126,444 141,348 Total notes payable 791,444 806,348 Less: current maturities (726,800 ) (725,920 ) Notes payable $ 64,644 $ 80,428 The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 13,961 11,836

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 9 – Convertible Notes Payable Related Party Convertible notes payable consist of the following at December 31, 2022 and September 30, 2022, respectively: Schedule of Related Party Convertible Notes Payable December 31, September 30, 2022 2022 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 5 $ 350,000 $ 350,000 Total convertible notes payable 350,000 350,000 Less: unamortized debt discounts (32,403 ) (39,728 ) Total convertible debt 317,597 310,272 Less: current maturities - - Convertible notes payable $ 317,597 $ 310,272 Convertible notes payable consist of the following at December 31, 2022 and September 30, 2022, respectively: Schedule of Convertible Notes Payable December 31, September 30, 2022 2022 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 150,000 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,470 98,188 February 11, 2024 4,621,105 0.0074 32,166 355,470 718,234 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 0.0074 31,671 350,000 350,000 On October 1, 2022, The Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 0.0074 30,102 362,765 - On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,418,235 1,418,234 Less: unamortized debt discounts (97,386 ) (45,039 ) Total convertible debt 1,320,849 1,373,195 Less: current maturities 150,000 1,198,469 Convertible notes payable $ 1,170,849 $ 174,726 In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to of $ 93,938 48,916 19,766 129,790 All of the convertible notes limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99 The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $ 36,236 26,567 The Company recognized interest expense for the three months ended December 31, 2022 and 2021, respectively, as follows: Schedule of Interest Expense December 31, December 31, 2022 2021 Interest on capital leases $ 1,961 $ 3,601 Interest on notes payable 12,000 17,753 Amortization of beneficial conversion features 48,916 19,766 Interest on convertible notes 36,236 28,273 Total interest expense $ 99,113 $ 69,393

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Equity	Note 10 – Stockholders’ Equity Preferred Stock The Company is authorized to issue 10,000,000 0.001 6,000,000 1,500,000 1,000 2,499,000 1,047,942 333,600 1,000 Series A The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,047,942 shares of Series A Preferred outstanding at December 31, 2022 are convertible into 5,239,710 shares of the common stock of the Company. No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series A Preferred and include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99 ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100 ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99 ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. Series B The Series B Preferred were designated on December 29, 2021. Each share of Series B Preferred has a Stated Value of $ 1.00 0.04 333,600 8,340,000 No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice Additional terms of the Series B Preferred and include the following: ● The shares of Series B Preferred are not entitled to dividends, provided that if dividends are paid on the shares of common stock of the Company, the Series B Preferred will be entitled to dividends based on the number shares of common stock which the Series B Preferred may then be converted. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends. ● Each share of Series B Preferred carries a number of votes equal to the number of shares of common stock into which such Series B Preferred may then be converted. Due to the change in control provision of the Series B Preferred, the Series B Preferred is classified as temporary equity on the balance sheet. Series C The Series C Preferred were designated on July 20, 2022. The principal feature of the Series C Preferred Stock is that it provides the holder thereof, so long as he or she is an executive officer of the Company, with the ability to vote with the holders of the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock 0.10 Common Stock Common stock consists of $ 0.001 250,000,000 82,296,820 During the three months ended December 31, 2022, the Company issued 7,150,000 71,745

Common Stock Options

Common Stock Options	3 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Common Stock Options	Note 11 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012, and terminated on March 5, 2022. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 Amortization of Stock-Based Compensation A total of $ 8,306 33,457 6,876 The following is a summary of information about the stock options outstanding at December 31, 2022. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.02 0.13 6,020,000 5.76 $ 0.07 5,680,714 $ 0.07 The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2022 6,020,000 $ 0.07 Options issued - - Options forfeited - - Balance, December 31, 2022 6,020,000 $ 0.07 Exercisable, December 31, 2022 5,680,714 $ 0.07 As of December 31, 2022, these options in the aggregate had no intrinsic value as the per share market price of $ 0.007 0.07

Common Stock Warrants

Common Stock Warrants	3 Months Ended
	Dec. 31, 2022
Common Stock Warrants
Common Stock Warrants	Note 12 – Common Stock Warrants Warrants to purchase a total of 15,387,050 The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2022 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.10 0.007 15,387,050 9.51 $ 0.02 15,387,050 $ 0.02 The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2022 1,500,000 $ 0.10 Warrants granted 13,887,050 $ 0.01 Warrants expired - - Balance, December 31, 2022 15,387,050 $ 0.02 Exercisable, December 31, 2022 15,387,050 $ 0.02 As of December 31, 2022, these warrants in the aggregate had no intrinsic value as the per share market price of $ 0.007 0.02

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13 – Commitments and Contingencies Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events On January 18, 2023, the Company issued 4,400,000 32,120 On January 26, 2023, the Company issued 2,100,000 0.0056 5.75

Organization, Basis of Presen_2

Organization, Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Organization	Organization Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and hopes to open labs in other states that have legalized the sale of cannabis, beginning with California or Arizona.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2022: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc. (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short-term nature of the instruments.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the three months ended December 31, 2022 and 2021, potential dilutive securities of 91,161,317 50,368,696 6,020,000 6,020,000 15,387,050 2,535,001 13,579,710 13,579,710
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity).

Organization, Basis of Presen_3

Organization, Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2022: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Digipath, Inc. (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of December 31, 2022 and September 30, 2022, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at December 31, 2022 Level 1 Level 2 Level 3 Assets Cash $ 155,832 $ - $ - Liabilities Lease liabilities - - 305,246 Notes payable - 791,444 - Convertible notes payable, net of discounts of $ 97,387 - - 1,320,849 Convertible notes payable – related parties, net of discounts of $ 32,403 - - 317,597 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 56,168 $ - $ - Liabilities Lease liabilities - - 330,510 Notes payable - 806,348 - Convertible notes payable, net of discounts of $ 45,039 - - 1,373,195 Convertible notes payable – related parties, net of discounts of $ 39,728 - - 310,272 Convertible notes payable, net - - 1,373,195 Convertible notes payable – related parties, net - - 310,272

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at December 31, 2022 and September 30, 2022: Schedule of Fixed Assets December, September 30, 2022 2022 Software $ 125,903 $ 125,903 Office equipment 80,343 71,601 Furniture and fixtures 29,879 29,879 Lab equipment 1,400,479 1,455,479 Leasehold improvements 510,076 510,076 Lab equipment held under capital leases 99,193 99,193 Fixed assets, gross 2,245,873 2,292,131 Less: accumulated depreciation (1,867,067 ) (1,831,308 ) Total $ 378,806 $ 460,823

Leases (Tables)

Leases (Tables)	3 Months Ended
	Dec. 31, 2022
Leases
Schedule of Components of Lease Expense	The components of lease expense were as follows: Schedule of Components of Lease Expense For the For the Three Months Ended Three Months Ended December 31, December 31, 2022 2021 Operating lease cost $ 29,718 $ 29,718 Finance lease cost: Amortization of assets - 8,467 Interest on lease liabilities - 809 Total net lease cost $ 29,718 $ 38,994
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows: Schedule of Supplemental Balance Sheet Information December 31, September 30, 2022 2022 Operating leases: Operating lease assets $ 291,869 $ 316,961 Current portion of operating lease liabilities 105,649 $ 100,685 Noncurrent operating lease liabilities 199,597 229,825 Total operating lease liabilities $ 305,246 $ 330,510 Finance lease: Equipment, at cost $ 99,193 $ 99,193 Accumulated amortization (64,475 ) (59,516 ) Equipment, net $ 34,718 $ 39,677 Weighted average remaining lease term: Operating leases 2.67 2.92 Weighted average discount rate: Operating leases 5.75 % 5.75 %
Schedule of Supplemental Cash Flow and Other Information	Supplemental cash flow and other information related to leases was as follows: Schedule of Supplemental Cash Flow and Other Information For the Three For the Three Months Ended Months Ended December 31, December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used for operating leases $ 29,532 $ 22,582 Financing cash flows used for finance leases $ - $ 8,467 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ - $ - Total finance lease liabilities $ - $ -
Schedule of Future Minimum Annual Lease Commitments Under Operating Leases	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of December 31, 2022: Schedule of Future Minimum Annual Lease Commitments Under Operating Leases Fiscal Year Ending Minimum Lease September 30, Commitments 2023 $ 89,936 2024 123,543 2025 116,891 2026 - 2027 - Total future undiscounted lease payments 330,370 Less interest 25,124 Present value of lease payments 305,246 Less current portion 105,649 Long-term operating lease liabilities $ 199,597

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Dec. 31, 2022
Long-Term Debt, Unclassified [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at December 31, 2022 and September 30, 2022, respectively: Schedule of Notes Payable December 31, 2022 September 30, 2022 On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 125,000 $ 665,000 $ 665,000 On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 126,444 141,348 Total notes payable 791,444 806,348 Less: current maturities (726,800 ) (725,920 ) Notes payable $ 64,644 $ 80,428

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Related Party Convertible Notes Payable	Related Party Convertible notes payable consist of the following at December 31, 2022 and September 30, 2022, respectively: Schedule of Related Party Convertible Notes Payable December 31, September 30, 2022 2022 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 5 $ 350,000 $ 350,000 Total convertible notes payable 350,000 350,000 Less: unamortized debt discounts (32,403 ) (39,728 ) Total convertible debt 317,597 310,272 Less: current maturities - - Convertible notes payable $ 317,597 $ 310,272
Schedule of Convertible Notes Payable	Convertible notes payable consist of the following at December 31, 2022 and September 30, 2022, respectively: Schedule of Convertible Notes Payable December 31, September 30, 2022 2022 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 150,000 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,470 98,188 February 11, 2024 4,621,105 0.0074 32,166 355,470 718,234 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 0.0074 31,671 350,000 350,000 On October 1, 2022, The Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 0.0074 30,102 362,765 - On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 150,000 150,000 Total convertible notes payable 1,418,235 1,418,234 Less: unamortized debt discounts (97,386 ) (45,039 ) Total convertible debt 1,320,849 1,373,195 Less: current maturities 150,000 1,198,469 Convertible notes payable $ 1,170,849 $ 174,726
Schedule of Interest Expense	The Company recognized interest expense for the three months ended December 31, 2022 and 2021, respectively, as follows: Schedule of Interest Expense December 31, December 31, 2022 2021 Interest on capital leases $ 1,961 $ 3,601 Interest on notes payable 12,000 17,753 Amortization of beneficial conversion features 48,916 19,766 Interest on convertible notes 36,236 28,273 Total interest expense $ 99,113 $ 69,393

Common Stock Options (Tables)

Common Stock Options (Tables)	3 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at December 31, 2022. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.02 0.13 6,020,000 5.76 $ 0.07 5,680,714 $ 0.07
Schedule of Activity of Outstanding Common Stock Options	The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2022 6,020,000 $ 0.07 Options issued - - Options forfeited - - Balance, December 31, 2022 6,020,000 $ 0.07 Exercisable, December 31, 2022 5,680,714 $ 0.07

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	3 Months Ended
	Dec. 31, 2022
Common Stock Warrants
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2022 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.10 0.007 15,387,050 9.51 $ 0.02 15,387,050 $ 0.02
Schedule of Outstanding Common Stock Warrants Activity	The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2022 1,500,000 $ 0.10 Warrants granted 13,887,050 $ 0.01 Warrants expired - - Balance, December 31, 2022 15,387,050 $ 0.02 Exercisable, December 31, 2022 15,387,050 $ 0.02

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	3 Months Ended
	Dec. 31, 2022
Entities Under Common Control and Ownership One [Member]
Name of Entity	Digipath, Inc.	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Parent
Entities Under Common Control and Ownership Two [Member]
Name of Entity	Digipath Labs, Inc.
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Three [Member]
Name of Entity	Digipath Labs CA, Inc	[2]
Jurisdiction of Incorporation	California
Relationship	Subsidiary
Entities Under Common Control and Ownership Four [Member]
Name of Entity	Digipath Labs S.A.S.	[3]
Jurisdiction of Incorporation	Colombia
Relationship	Subsidiary
Entities Under Common Control and Ownership Five [Member]
Name of Entity	VSSL Enterprises, Ltd.	[4]
Jurisdiction of Incorporation	Canada
Relationship	Subsidiary
[1]Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.[2]Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations.[3]Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.[4]Acquired on March 11, 2020.

Organization, Basis of Presen_4

Organization, Basis of Presentation and Significant Accounting Policies (Details Narrative) - shares	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities earning per share	13,579,710
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities earning per share	13,579,710
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities earning per share	91,161,317	50,368,696
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities earning per share	6,020,000	6,020,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities earning per share	15,387,050	2,535,001

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working Capital	$ 1,465,347
Accumulated deficit	20,249,101	$ 20,008,771
Cash	$ 155,832	$ 56,168

Summary of Financial Instrument

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash	$ 155,832	$ 56,168
Lease liabilities
Notes payable
Convertible notes payable, net
Convertible notes payable – related parties, net
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash
Lease liabilities
Notes payable	791,444	806,348
Convertible notes payable, net
Convertible notes payable – related parties, net
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash
Lease liabilities	305,246	330,510
Notes payable
Convertible notes payable, net	1,320,849	1,373,195
Convertible notes payable – related parties, net	$ 317,597	$ 310,272

Summary of Financial Instrume_2

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Convertible Debt [Member]
Short-Term Debt [Line Items]
Convertible notes discounts		$ 45,039
Convertible Debt Related Parties [Member]
Short-Term Debt [Line Items]
Convertible notes discounts		$ 39,728
Convertible Debt [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 97,387
Convertible Debt Related Parties [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 32,403

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	3 Months Ended
	Dec. 31, 2022 USD ($)
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Service for incurred fees	$ 15,000
Due to related party	30,000
Board Of Directors [Member]
Related Party Transaction [Line Items]
Service for incurred fees	21,000
Due to related party	$ 147,000

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)					2 Months Ended	13 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 08, 2022	Feb. 14, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 23, 2021	Jun. 13, 2019	Dec. 28, 2018
Defined Benefit Plan Disclosure [Line Items]
Purchase price note receivable						$ 100,000
Northwest Analytical Labs, Inc. [Member]
Defined Benefit Plan Disclosure [Line Items]
Loan received from related party									$ 95,000	$ 95,000
Debt instrument stated percentage									10%	10%
C3 Labs, Inc., [Member]
Defined Benefit Plan Disclosure [Line Items]
Loan received from related party						$ 1,047,649		$ 1,047,649
Debt instrument stated percentage						8%		8%
Debt Instrument, Maturity Date						Aug. 23, 2022
Interest receivable						$ 64,017
Invictus Wealth Group [Member] | Asset Purchase Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Debt instrument stated percentage				10%
Debt Instrument, Maturity Date				Dec. 31, 2023
Purchase price note receivable				$ 900,000
Upfront payment				275,000
Purchase price note receivable				$ 625,000
Invictus Wealth Group [Member] | Asset Purchase Agreement [Member] | Subsequent Event [Member]
Defined Benefit Plan Disclosure [Line Items]
Upfront payment					$ 275,000
Received portion of upfront payment					$ 100,000
Invictus Wealth Group [Member] | Asset Purchase Agreement [Member] | Forecast [Member]
Defined Benefit Plan Disclosure [Line Items]
Debt final payment	$ 425,000	$ 100,000	$ 100,000

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Software	$ 125,903	$ 125,903
Office equipment	80,343	71,601
Furniture and fixtures	29,879	29,879
Lab equipment	1,400,479	1,455,479
Leasehold improvements	510,076	510,076
Lab equipment held under capital leases	99,193	99,193
Fixed assets, gross	2,245,873	2,292,131
Less: accumulated depreciation	(1,867,067)	(1,831,308)
Total	$ 378,806	$ 460,823

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 35,759	$ 58,469
Impairment expense	$ 55,000

Schedule of Components of Lease

Schedule of Components of Lease Expense (Details) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating lease cost	$ 29,718	$ 29,718
Amortization of assets		8,467
Interest on lease liabilities		809
Total net lease cost	$ 29,718	$ 38,994

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Leases
Operating lease assets	$ 291,869	$ 316,961
Current portion of operating lease liabilities	105,649	100,685
Noncurrent operating lease liabilities	199,597	229,825
Total operating lease liabilities	305,246	330,510
Equipment, at cost	99,193	99,193
Accumulated amortization	(64,475)	(59,516)
Equipment, net	$ 34,718	$ 39,677
Weighted average remaining lease term operating leases	2 years 8 months 1 day	2 years 11 months 1 day
Weighted average discount rate operating leases	5.75%	5.75%

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow and Other Information (Details) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating cash flows used for operating leases	$ 29,532	$ 22,582
Financing cash flows used for finance leases		8,467
Total operating lease liabilities
Total finance lease liabilities

Schedule of Future Minimum Annu

Schedule of Future Minimum Annual Lease Commitments Under Operating Leases (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Leases
2023	$ 89,936
2024	123,543
2025	116,891
2026
2027
Total future undiscounted lease payments	330,370
Less interest	25,124
Present value of lease payments	305,246	$ 330,510
Less current portion	105,649	100,685
Long-term operating lease liabilities	$ 199,597	$ 229,825

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended
	Dec. 31, 2022
Leases
Lease Expiration Date	Aug. 31, 2025

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Short-Term Debt [Line Items]
Total notes payable	$ 791,444	$ 806,348
Less: current maturities	(726,800)	(725,920)
Notes payable	64,644	80,428
Notes Payable One [Member]
Short-Term Debt [Line Items]
Total notes payable	665,000	665,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total notes payable	$ 126,444	$ 141,348

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)			3 Months Ended		12 Months Ended
	Sep. 10, 2021	Dec. 26, 2019	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Short-Term Debt [Line Items]
Repayments of notes payable			$ 14,904	$ 14,142
Canna Lab Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 675,000
Debt instrument interest percentage	12%
Debt Instrument, Maturity Date	Sep. 10, 2024
Debt instrument periodic payment	$ 22,419.66
Debt conversion original debt amount					$ 115,000
Repayments of notes payable					$ 125,000
Note Payable [Member]
Short-Term Debt [Line Items]
Debt instrument interest percentage		5.75%
Debt Instrument, Maturity Date		Dec. 26, 2024
Debt instrument periodic payment		$ 5,622
Payments for lab equipment		377,124
Proceeds from bank loan		$ 291,931
Debt instrument term description		5 years

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Note Payable [Member]
Short-Term Debt [Line Items]
Interest expense	$ 13,961	$ 11,836

Schedule of Related Party Conve

Schedule of Related Party Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Short-Term Debt [Line Items]
Total convertible notes payable	$ 1,418,235	$ 1,418,234
Total convertible debt	1,320,849	1,373,195
Less: current maturities	150,000	1,198,469
Convertible notes payable	1,170,849	174,726
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	50,000	50,000
Related Party Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Less: unamortized debt discounts	(32,403)	(39,728)
Total convertible debt	317,597	310,272
Less: current maturities
Convertible notes payable	317,597	310,272
Related Party Convertible Notes Payable [Member] | Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	$ 350,000	$ 350,000

Schedule of Related Party Con_2

Schedule of Related Party Convertible Notes Payable (Details) (Parenthetical) - USD ($)					3 Months Ended
	Aug. 08, 2022	Dec. 29, 2020	Dec. 28, 2020	Feb. 10, 2020	Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Proceeds from convertible note
9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]
Short-Term Debt [Line Items]
Debt principal amount			$ 400,000	$ 350,000
Debt Instrument, Maturity Date	Feb. 11, 2024			Aug. 10, 2022
Outstanding common shares, percentage	5%			9%
Conversion price per share		$ 0.03	$ 0.03	$ 0.15
Proceeds from convertible note			$ 50,000
Debt converted principal amount		$ 50,000
Debt converted principal value, shares		1,666,667
Shares of common stock issued	4,550,000
Debt instrument fair value	$ 43,788

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Short-Term Debt [Line Items]
Total convertible notes payable	$ 1,418,235	$ 1,418,234
Less: unamortized debt discounts	(97,386)	(45,039)
Total convertible debt	1,320,849	1,373,195
Less: current maturities	150,000	1,198,469
Convertible notes payable	1,170,849	174,726
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	150,000	150,000
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	355,470	718,234
Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	362,765
Convertible Notes Payable Six [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	$ 150,000	$ 150,000

Schedule of Convertible Notes_2

Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

3 Months Ended

12 Months Ended

Oct. 02, 2022

Aug. 11, 2022

Aug. 08, 2022

Sep. 30, 2021

Feb. 22, 2021

Dec. 29, 2020

Dec. 28, 2020

Sep. 30, 2020

Feb. 11, 2020

Feb. 10, 2020

Sep. 23, 2019

Nov. 08, 2018

Nov. 05, 2018

Dec. 31, 2022

Dec. 31, 2021

Oct. 30, 2022

Short-Term Debt [Line Items]

Proceeds from convertible debt

Amortization of debt discount premium

$ 48,916

$ 19,766

9% Secured Convertible Promissory Note [Member] | Accredited Investors One [Member]

Short-Term Debt [Line Items]

Debt principal amount

$ 60,000

$ 50,000

Debt instrument maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price per share

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 10,000

Debt converted principal amount

$ 10,000

Debt converted principal value, shares

333,334

Shares of common stock issued

650,000

Debt instrument fair value

$ 6,989

9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Debt principal amount

$ 400,000

$ 350,000

Debt instrument maturity date

Feb. 11, 2024

Aug. 10, 2022

Debt instrument interest percentage

5%

9%

Conversion price per share

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 50,000

Debt converted principal amount

$ 50,000

Debt converted principal value, shares

1,666,667

Shares of common stock issued

4,550,000

Debt instrument fair value

$ 43,788

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Debt principal amount

$ 200,000

$ 150,000

Debt instrument maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price per share

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 50,000

Debt converted principal amount

$ 50,000

Debt converted principal value, shares

1,666,667

Shares of common stock issued

1,950,000

Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Debt instrument fair value

$ 20,968

Senior Secured Convertible Note [Member]

Short-Term Debt [Line Items]

Debt instrument maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price per share

$ 0.03

$ 0.03

$ 0.11

Proceeds from convertible debt

$ 200,000

Debt converted principal amount

$ 90,000

Debt converted principal value, shares

3,000,000

Debt instrument periodic payment

$ 355,470

Amortization of debt discount premium

$ 98,188

Debt instrument purchase of warrant

4,621,105

Debt instrument ecercise price

$ 0.0074

Debt instrument fair value of warrant

$ 32,166

Senior Secured Convertible Note One [Member]

Short-Term Debt [Line Items]

Debt instrument maturity date

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price per share

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 350,000

Debt instrument purchase of warrant

4,550,000

Debt instrument ecercise price

$ 0.0074

Debt instrument fair value of warrant

$ 31,671

Senior Secured Convertible Note Two [Member]

Short-Term Debt [Line Items]

Debt instrument maturity date

Feb. 11, 2024

Debt instrument interest percentage

8%

Conversion price per share

$ 0.01

Debt instrument purchase of warrant

4,715,945

Debt instrument ecercise price

$ 0.0074

Debt instrument fair value of warrant

$ 30,102

Debt conversion original debt amount

$ 362,765

Senior Secured Convertible Note Three [Member]

Short-Term Debt [Line Items]

Debt instrument maturity date

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price per share

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 150,000

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Interest on capital leases	$ 1,961	$ 3,601
Interest on notes payable	12,000	17,753
Amortization of beneficial conversion features	48,916	19,766
Interest on convertible notes	36,236	28,273
Total interest expense	$ 99,113	$ 69,393

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Amortization of debt discounts	$ 48,916	$ 19,766
Maximum Share Amount [Member]
Short-Term Debt [Line Items]
Maximum amount owned percentage of issued and outstanding common shares	4.99%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt discount conversion feature of convertible debt	$ 93,938
Amortization of debt discounts	48,916	19,766
Unamortized discounts	129,790
Convertible notes interest expense	$ 36,236	$ 26,567

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2022	Sep. 30, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized	10,000,000
Preferred stock, par value	$ 0.001
Conversion of stock shares issued	8,340,000
Common stock par value	$ 0.001	$ 0.001
Common stock authorized	250,000,000	250,000,000
Common stock, shares outstanding	82,296,820	75,146,820
Issuance of common shares to settle stock payable
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,047,942	1,047,942
Preferred stock, shares outstanding	1,047,942	1,047,942
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	333,600
Temporary equity, shares outstanding	333,600	333,600
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	1,000
Preferred stock, shares designated remaining	2,499,000
Preferred stock, shares issued	1,000
Preferred stock, shares outstanding	1,000
Preferred stock voting rights	$ 0.10
Preferred stock voting rights	the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion shares converted	1,047,942
Convertible Preferred Stock, Shares Issued upon Conversion	5,239,710
Common Stock, Terms of Conversion	No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice.
Purchase price	100%
Series A Preferred Stock [Member] | Noteholders [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership	4.99%
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 1
Conversion shares converted	333,600
Common Stock, Terms of Conversion	No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice
Preferred stock voting rights	$ 0.04
Conversion of stock description	Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends.
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common shares to settle stock payable, shares	7,150,000
Issuance of common shares to settle stock payable	$ 71,745

Summary of Common Stock Options

Summary of Common Stock Options Outstanding (Details)	3 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, Minimum	$ 0.02
Range of Exercise Price, Maximum	$ 0.13
Number of Options Outstanding | shares	6,020,000
Weighted Average Remaining Contractual Life	5 years 9 months 3 days
Weighted Average Exercise Price	$ 0.07
Number of Shares Exercisable | shares	5,680,714
Weighted Average Exercise Price Exercisable	$ 0.07

Schedule of Activity of Outstan

Schedule of Activity of Outstanding Common Stock Options (Details)	3 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Shares Outstanding, Beginning balance | shares	6,020,000
Weighted Average Exercise Price, Outstanding, Beginning Balance | $ / shares	$ 0.07
Number of Shares Outstanding, Option Issued | shares
Weighted Average Exercise Price, Options issued | $ / shares
Number of Shares Outstanding, Option Forfeited | shares
Weighted Average Exercise Price, Options Forfeited | $ / shares
Number of Shares Outstanding, Ending balance | shares	6,020,000
Weighted Average Exercise Price, Outstanding, Ending Balance | $ / shares	$ 0.07
Number of Shares Exercisable | shares	5,680,714
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.07

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)		3 Months Ended
	Jun. 21, 2016	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Intrinsic value, market price per share		$ 0.007
Intrinsic value weighted-average exercise price per share		$ 0.07
Amortization of Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses		$ 8,306	$ 33,457
Unamortized expenses expected to be expensed		$ 6,876
2012 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued under stock plan	11,500,000

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details)	3 Months Ended
	Dec. 31, 2022 $ / shares shares
Common Stock Warrants
Range of Exercise Price, Minimum	$ 0.10
Range of Exercise Price, Maximum	$ 0.007
Number of Warrants Outstanding | shares	15,387,050
Weighted Average Remaining Contractual Life	9 years 6 months 3 days
Weighted Average Exercise Price	$ 0.02
Number of Warrants Exercisable | shares	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.02

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants Activity (Details)	3 Months Ended
	Dec. 31, 2022 $ / shares shares
Common Stock Warrants
Number of Shares, Balance beginning | shares	1,500,000
Weighted Average Exercise Price, Balance beginning | $ / shares	$ 0.10
Number of Shares, Warrants granted | shares	13,887,050
Weighted Average Exercise Price, Warrants granted | $ / shares	$ 0.01
Number of Shares, Warrants expired | shares
Weighted Average Exercise Price, Warrants expired | $ / shares
Number of Shares, Balance ending | shares	15,387,050
Weighted Average Exercise Price, Balance, ending | $ / shares	$ 0.02
Number of Shares, Exercisable | shares	15,387,050
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.02

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative)	3 Months Ended
	Dec. 31, 2022 $ / shares shares
Number of warrant to purchase of common stock shares | shares	15,387,050
Intrinsic value, market price per share	$ 0.007
Intrinsic value weighted-average exercise price per share	0.07
Warrant [Member]
Intrinsic value, market price per share	0.007
Intrinsic value weighted-average exercise price per share	$ 0.02

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)			3 Months Ended
	Jan. 26, 2023	Jan. 18, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Issuance of stock, value				$ 52,500
Option to purchase common stock
Subsequent Event [Member] | Officers and Directors [Member]
Subsequent Event [Line Items]
Issuance of stock, shares		4,400,000
Issuance of stock, value		$ 32,120
Subsequent Event [Member] | Employees [Member]
Subsequent Event [Line Items]
Option to purchase common stock	2,100,000
Stock option exercise price	$ 0.0056
Stock option vesting years	5 years 9 months